A. Bashey

发表

The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation.

M. Solh, D. Speckhart, S. Solomon, 2020, Blood advances.

Survival following allogeneic transplant in patients with myelofibrosis.

N. Kröger, M. Arcasoy, S. Verstovsek, 2020, Blood advances.

In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden.

A. Vitiello, R. Bejar, Bjoern Peters, 2020, Cytotherapy.

Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables.

M. Solh, S. Solomon, A. Bashey, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Proliferative but not nonproliferative responses to granulocyte colony-stimulating factor are associated with rapid activation of the p21ras/MAP kinase signalling pathway.

A. Bashey, L. Healy, C. Marshall, 1994, Blood.

Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia.

K. Messer, Minya Pu, J. Castro, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Extramedullary acute myelogenous leukemia.

M. Solh, S. Solomon, A. Bashey, 2016, Blood reviews.

Current Status of BoneMarrow Transplantation for Treatment of Cancer

J. Castro, T. Lane, E. Ball, 2011 .

Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia

J. Cortes, M. Grunwald, R. Stuart, 2020, JCO oncology practice.

Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy.

S. Solomon, B. Smith, S. Gore, 2015, Clinical Lymphoma, Myeloma & Leukemia.

Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients.

M. Aljurf, J. Szer, R. Gale, 2021, Transplantation and cellular therapy.

A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients.

R. Vij, W. Wood, M. Aljurf, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.

M. Sorror, M. Krem, M. Pasquini, 2021, Transplantation and cellular therapy.

Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR.

S. Montoto, M. Perales, I. Yakoub-Agha, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant.

K. Ballen, O. Ringdén, D. Rizzieri, 2020, Biology of Blood and Marrow Transplantation.

Allogeneic hematopoietic cell transplantation for metastatic breast cancer

D. Blaise, N. Ueno, D. Niederwieser, 2008, Bone Marrow Transplantation.

transplantation for follicular lymphoma Comparison of autologous and allogeneic hematopoietic stem cell

J. Armitage, J. Vose, M. Horowitz, 2013 .

A multicenter, phase I study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.

Catherine J. Wu, J. Ritz, S. Nikiforow, 2020, Blood.

Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure

J. Vose, Sonali M. Smith, R. Vij, 2018, Cancer.

Non-Myeloablative Allogeneic Transplantation

E. Ball, A. Bashey, 2002, Cancer Treatment and Research.

Mutational activation of the N-ras oncogene assessed in primary clonogenic culture of acute myeloid leukemia (AML): implications for the role of N-ras mutation in AML pathogenesis.

C. Marshall, A. Bashey, R. Clutterbuck, 1992, Blood.

A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia

K. Messer, Hongying Li, E. Ball, 2018, Clinical lymphoma, myeloma & leukemia.

Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome

H. Deeg, D. Porter, G. Gui, 2020, medRxiv.

The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation

S. Solomon, D. Blaise, A. Nagler, 2019, Bone Marrow Transplantation.

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

P. Hari, S. Mineishi, P. Armand, 2017, Blood.

Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era

P. Hari, Shaji K. Kumar, R. Gale, 2020, Leukemia.

Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.

R. Vij, D. Lad, M. Perales, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outpatient myeloablative allo-SCT: a comprehensive approach yields decreased hospital utilization and low TRM

D. Speckhart, A. Bashey, L. Morris, 2010, Bone Marrow Transplantation.

Low Dose Subcutaneous Alemtuzumab and Prophylactic Donor Lymphocyte Infusion Results in Favorable Outcomes for High Risk Recipients of Unrelated Donor Allogeneic Transplants.

S. Solomon, A. Bashey, L. Morris, 2009 .

Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells

T. Kipps, A. Bashey, M. Cantwell, 2002, British journal of haematology.

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.

I. Lowy, R. Soiffer, E. Ball, 2009, Blood.

CTLA 4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

I. Lowy, R. Soiffer, E. Ball, 2009 .

CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells.

K. Messer, I. Lowy, R. Soiffer, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations.

J. Fay, M. Horowitz, R. Gale, 2005, Blood.

COMPARISON OF GRAFT-VS-HOST-DISEASE AND SURVIVAL AFTER HLA- IDENTICAL SIBLING BONE MARROW TRANSPLANTATION IN DIFFERENT ETHNIC POPULATIONS Running Head: Graft-vs-host disease in ethnic populations For Submission to BLOOD, Clinical Observations

J. Fay, M. Horowitz, R. Gale, 2004 .

Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.

E. Leifer, N. Geller, D. Porter, 2021, Transplantation and cellular therapy.

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

R. Vij, M. Perales, F. Appelbaum, 2015, Blood.

Correlation Between IL‐3 Receptor Expression and Growth Potential of Human CD34+ Hematopoietic Cells from Different Tissues

A. Ho, A. Bashey, Shiang Huang, 1999, Stem cells.

Outcome of transplantation for myelofibrosis.

N. Kröger, M. Horowitz, R. Gale, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Lineage-Specific Relapse Prediction Following Haploidentical Transplant with Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group KIR Ligand.

M. Solh, S. Solomon, A. Bashey, 2022, Transplantation and cellular therapy.

Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide.

M. Solh, S. Solomon, A. Bashey, 2020, Blood advances.

Simultaneous administration of G-CSF and GM-CSF for re-mobilization in patients with inadequate initial progenitor cell collections for autologous transplantation.

A. Ho, K. Fields, T. Lane, 2000, Cytotherapy.

Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older.

J. Castro, T. Lane, E. Ball, 2006, Leukemia research.

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry.

J. Vose, M. Horowitz, R. Gale, 2004, Blood.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia.

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.

E. Leifer, N. Geller, H. Deeg, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

K. Owzar, C. Hofmeister, R. Vij, 2010 .

Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901.

K. Owzar, P. Westervelt, S. Farag, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.

Alan M. Miller, Sonali M. Smith, R. Vij, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reduced-intensity allografting as first transplantation approach in relapsed/refractory grade 1-2 follicular lymphoma provides improved outcomes in long-term survivors Biol Blood Marrow Transplant

Alan M. Miller, Sonali M. Smith, R. Vij, 2015 .

Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older

M. Solh, S. Solomon, A. Bashey, 2018, Bone Marrow Transplantation.

Peripheral blood progenitor cell mobilization with intermediate‐dose cyclophosphamide, sequential granulocyte‐macrophage–colony‐stimulating factor and granulocyte–colony‐stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation

M. Donohue, R. Xu, J. Castro, 2007, Transfusion.

Donor cell Leukaemia – an unresolved problem

A. Bashey, S. Brown, S. Schey, 1995, European journal of haematology.

Non‐lymphoid blast crisis of CML with rearrangement of immunoglobulin and T‐cell receptor delta genes

T. Vulliamy, J. Goldman, A. Schwarer, 1991, European journal of haematology.

Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.

S. Solomon, A. Bashey, L. Morris, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study

A. Viswabandya, Richard J. Jones, M. Grunwald, 2021, Leukemia.

The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation

D. Blaise, A. Nagler, M. Mohty, 2018, Bone Marrow Transplantation.

Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

E. Leifer, N. Geller, H. Deeg, 2015 .

Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study.

H. Atkins, P. Hari, A. Dispenzieri, 2010, Clinical lymphoma, myeloma & leukemia.

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT

J. Esteve, F. Baron, M. Labopin, 2019, Haematologica.

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Catherine J. Wu, F. Hodi, Michael S. Rooney, 2016, The New England journal of medicine.

Use of capecitabine as first-line therapy in patients with metastatic breast cancer relapsing after high-dose chemotherapy and autologous stem cell support.

E. Ball, A. Bashey, D. Lancaster, 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.

S. Solomon, A. Bashey, L. Morris, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation.

P. Hari, R. Kyle, Shaji K. Kumar, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparison of twin and autologous transplants for multiple myeloma.

R. Fonseca, P. Hari, R. Kyle, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Induction of molecular remission by donor peripheral blood leukocyte therapy in patients relapsing with extramedullary blastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation.

J. Wang-Rodriguez, A. Ho, A. Bashey, 1998, Oncology reports.

Safety and efficacy of rituximab-based first line treatment of chronic GVHD

M. Solh, S. Solomon, A. Bashey, 2018, Bone Marrow Transplantation.

Sequential acquisition of trisomy 8 and N‐ras mutation in acute myeloid leukaemia demonstrated by analysis of isolated leukaemic colonies

C. Marshall, C. Price, A. Bashey, 1994, British journal of haematology.

A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies

M. Solh, S. Solomon, A. Bashey, 2021, Advances in hematology.

Who is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidenitcal Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?

M. Solh, S. Solomon, A. Bashey, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.

S. Solomon, A. Bashey, L. Morris, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial.

S. Solomon, A. Bashey, L. Morris, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine).

M. Solh, S. Solomon, A. Bashey, 2020, Leukemia research.

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

R. Vij, M. Perales, F. Appelbaum, 2015, Blood.

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.

H. Deeg, D. Porter, G. Gui, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide after stem-cell transplantation for multiple myeloma.

K. Owzar, C. Hofmeister, R. Vij, 2012, The New England journal of medicine.

Correction: The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation

D. Blaise, A. Nagler, M. Mohty, 2018, Bone Marrow Transplantation.

Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

M. Krem, C. Hourigan, M. Aljurf, 2021, Blood advances.

HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis.

H. Chu, D. Weisdorf, A. Rashidi, 2019, Blood advances.

The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.

M. Solh, S. Solomon, A. Bashey, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mobilization of blood‐derived stem and progenitor cells in normal subjects by granulocyte‐macrophage‐ and granulocyte‐colony‐stimulating factors

T. Lane, A. Bashey, P. Law, 1999, Transfusion.

Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma.

P. Hari, R. Kyle, D. Reece, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk In

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Fevers post infusion of T-cell replete hla mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes

E. Dickhaus, M. Solh, S. Solomon, 2019, Bone Marrow Transplantation.

Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients

M. Solh, S. Solomon, A. Bashey, 2018, Bone Marrow Transplantation.

Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.

M. Solh, S. Solomon, A. Bashey, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide.

Shannon R. McCurdy, M. Perales, R. Soiffer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation.

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Post-relapse survival after haploidentical transplantation vs matched-related or matched-unrelated hematopoietic cell transplantation

M. Solh, S. Solomon, A. Bashey, 2016, Bone Marrow Transplantation.

Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide

M. Solh, S. Solomon, A. Bashey, 2016, Advances in hematology.

Haploidentical Transplantation Using T-Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors Is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of A Prospective Phase II Trial

S. Solomon, A. Bashey, L. Morris, 2011 .

Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma

Scott E. Smith, Sin-Ho Jung, K. Owzar, 2017, The Lancet. Haematology.

Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant.

M. Solh, S. Solomon, A. Bashey, 2020, Blood advances.

HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR.

R. Schlenk, H. Döhner, A. Ganser, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia.

A. Gratwohl, R. Gale, P. Tiberghien, 2000, Blood.

Late onset immune pancytopenia following bone marrow transplantation

M. McMullin, P. Mahendra, L. Tyfield, 1991, British journal of haematology.

Superior Survival of Black Versus White Patients Following Post-Transplant Cyclophosphamide-Based Haploidentical Transplantation for Adults with Hematologic Malignancy.

M. Solh, S. Solomon, A. Bashey, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide.

Shannon R. McCurdy, M. Norkin, M. Perales, 2018, Blood advances.

T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor

S. Solomon, A. Bashey, S. Solomon, 2014, Bone Marrow Transplantation.

Incidence and impact of community respiratory viral infections in post‐transplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis and haploidentical stem cell transplantation

M. Perales, M. Krem, P. Ljungman, 2021, British journal of haematology.

Myeloablative Conditioning With PBSC Grafts For T-Replete Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide Results In Universal Engraftment, Low Rates Of Gvhd, NRM and Excellent Survival Outcomes: An Analysis Of Two Consecutive Phase II Studies From a Si

Ocn, S. Jacobson, S. Solomon, 2013 .

Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia.

A. Nademanee, R. Champlin, S. Solomon, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.

S. Solomon, A. Bashey, L. Morris, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

TBI-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients without Matched Sibling Donors

S. Solomon, A. Bashey, L. Morris, 2014 .

HLA Informs Risk Predictions after Haploidentical Stem Cell Transplantation with Post-transplantation Cyclophosphamide.

Shannon R. McCurdy, M. Grunwald, Stephanie J. Lee, 2021, Blood.

Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia.

B. George, R. Gale, H. Lazarus, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

B. Sandmaier, M. Aljurf, R. Gale, 2019, Blood advances.

A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma.

Alan M. Miller, J. Armitage, J. Vose, 2003, Blood.

The effect of inter-unit HLA matching in double umbilical cord blood transplantation for acute leukemia

M. Perales, M. Territo, D. Weisdorf, 2017, Haematologica.

Current Graft-versus-Host Disease-Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant.

M. Solh, S. Solomon, A. Bashey, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation.

A. Ganser, M. Labopin, A. Nagler, 2020, Blood advances.

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.

N. Geller, A. Krishnan, R. Vij, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma

Scott E. Smith, Sin-Ho Jung, K. Owzar, 2017, The Lancet. Haematology.

A phase II study of two cycles of high-dose chemotherapy with autologous stem cell support in patients with metastatic breast cancer who meet eligibility criteria for a single cycle

A. Ho, T. Lane, A. Bashey, 2000, Bone Marrow Transplantation.

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

Ruta Bajorunaite, Arturo Molina, John Gibson, 2003, Blood.

Preferential depletion of host over donor T cells through in vivo decay of active rabbit-anti-thymocyte globulin levels during reduced intensity conditioning

A. Bashey, H. Holland, K. Connor, 2015, Bone Marrow Transplantation.

FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia

C. Hoh, T. Lane, E. Ball, 2003, Bone Marrow Transplantation.

Recurrent bone marrow necrosis and extramedullary myeloid deposits in Philadelphia negative chronic myeloid leukaemia.

J. Goldman, A. Bashey, I. Dokal, 1988, Haematologica.

Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR)

J. Armitage, R. Herzig, A. Bashey, 2001, Bone Marrow Transplantation.

Incidence and Impact of Cytomegalovirus Infection in Haploidentical and Matched-Related Donors Receiving Post-Transplant Cyclophosphamide (PTCy): A CIBMTR Analysis

M. Perales, K. Komanduri, R. Maziarz, 2020 .

Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era

P. Hari, Shaji K. Kumar, R. Gale, 2021, Leukemia.

Beneficial effect of intravenous lidocaine in cutaneous chronic graft-versus-host disease secondary to donor lymphocyte infusion

M. Coutinho, A. Bashey, P. Holman, 2001, Bone Marrow Transplantation.

UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF TGR‐1202 IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MCL OR CLL

M. Davids, D. Fisher, C. Jacobson, 2017 .

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report

J. Mehta, M. Perales, N. Saba, 2019, Clinical Cancer Research.

Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma.

D. Heitjan, P. Hari, R. Kyle, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study

M. Davids, D. Fisher, C. Jacobson, 2016 .

IS THE INTERNATIONAL STAGING SYSTEM SUPERIOR TO THE DURIE SALMON STAGING SYSTEM? A COMPARISON IN MULTIPLE MYELOMA PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANT

P. Hari, R. Kyle, D. Reece, 2009, Leukemia.

MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WHO RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LYMPHOMA: A REPORT OF THE INTERNATIONAL BONE MARROW TRANSPLANT REGISTRY Running head: Allogeneic transplants after autologous failure For Submission to BLOOD, Trans

J. Vose, M. Horowitz, R. Gale, 2004 .

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study

F. Ravandi, W. Stock, A. Pastore, 2020, Blood.

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study

H. Kantarjian, F. Ravandi, Koichi Takahashi, 2018, Blood.

Real-world outcomes of unselected elderly acute myeloid leukemia patients referred to a leukemia/hematopoietic cell transplant program

H. Kent Holland, M. Solh, S. Solomon, 2019, Bone Marrow Transplantation.

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

Matthew J. Frigault, R. Houot, V. Torri, 2021, Leukemia.

Extracorporeal photopheresis (ECP) improves overall survival in the treatment of steroid refractory acute graft-versus-host disease (SR aGvHD)

M. Solh, S. Solomon, A. Bashey, 2021, Bone Marrow Transplantation.

Post-Transplant Cyclophosphamide (PTCy) is Associated with Increased Cytomegalovirus Infection: A CIBMTR Analysis.

M. Perales, M. Krem, P. Ljungman, 2021, Blood.

Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.

J. Vose, Sonali M. Smith, P. Hari, 2008, Biology of Blood and Marrow Transplantation.

Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial

A. Bashey, H. Holland, S. Solomon, 2014, Bone Marrow Transplantation.

Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.

H. Goldschmidt, P. Hari, D. Reece, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia.

M. Norkin, B. Sandmaier, B. George, 2019, Blood advances.

High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma

E. Ball, A. Bashey, S. Corringham, 2004, Bone Marrow Transplantation.

Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.

A. Krishnan, R. Vij, P. Hari, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Fludarabine and Total Body Irradiation Conditioning Prior to Ablative Haploidentical Transplantation: Long-term Safety and Efficacy.

M. Solh, S. Solomon, A. Bashey, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.

M. Pasquini, J. Wingard, K. Ballen, 2019, Blood advances.

Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide

Shannon R. McCurdy, M. Perales, M. Horowitz, 2016 .

Peripheral blood stem cells for T cell-replete nonmyeloablative hematopoietic transplants using post-transplant cyclophosphamide.

A. Bashey, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Graft-versus-host disease prophylaxis

M. Solh, A. Bashey, 2017 .

Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors.

B. George, M. Grunwald, D. Weisdorf, 2021, Blood advances.

Shannon R. McCurdy, J. Bourhis, M. Labopin, 2018, Blood advances.

Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients

M. Solh, S. Solomon, A. Bashey, 2019, Blood.

Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.

J. Sierra, A. Zander, M. Horowitz, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Differences in GVHD Characteristics Between Haploidentical Transplantation Using Post-Transplant Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors.

M. Solh, S. Solomon, A. Bashey, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Title: Impact of Induction Therapy with VRD vs. VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.

Shaji K. Kumar, M. Aljurf, M. Qazilbash, 2021, Transplantation and cellular therapy.

T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes

M. Pasquini, J. Wingard, K. Ballen, 2018, Blood.

Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia.

C. Flowers, M. Perales, A. Viswabandya, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Hematopoietic Cell Transplantation (HCT) for Adult Patients with Acute Lymphoblastic Leukemia: Impact of Timely Transplantation on Survival Outcomes

M. Solh, S. Solomon, A. Bashey, 2022, Transplantation and Cellular Therapy.

An Effective Hematopoietic Stem Cell Mobilization Algorithm for Adding Plerixafor to G-CSF for Multiple Myeloma Patients Undergoing Autologous Transplantation

S. Solomon, A. Bashey, L. Morris, 2011 .

A Comparison Of Toxicity And Mobilization Efficacy Following Two Different Doses Of Cyclophosphamide For Mobilization Of Hematopoietic Stem Cells In Multiple Myeloma Patients

S. Solomon, A. Bashey, L. Morris, 2010 .

A Comparison of Toxicity and Mobilization Efficacy Following Two Different Doses of Cyclophosphamide for Mobilization of Hematopoietic Stem Cells in Multiple Myeloma Patients.

S. Solomon, A. Bashey, L. Morris, 2009 .

Non-Inferior Survival of Black Versus White Patients and Superior Outcomes for Black Females Compared to Other Race/Gender Groups Following Allogeneic Transplantation for Hematologic Malignancy: A Single Center Multivariable Analysis of 475 Allografted Patients

M. Solh, S. Solomon, A. Bashey, 2015 .

Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis

G. Sheean, A. Bashey, W. Baek, 2006, Journal of Neurology, Neurosurgery & Psychiatry.

High-dose Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Conditioning Prior to Autologous Transplantation for Patients with Multiple Myeloma.

M. Solh, S. Solomon, A. Bashey, 2022, Transplantation and Cellular Therapy.

Immunosuppression with limited toxicity: the characteristics of nucleoside analogs and anti-lymphocyte antibodies used in non-myeloablative hematopoietic cell transplantation.

A. Bashey, 2002, Cancer treatment and research.

Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma

N. Geller, A. Krishnan, P. Hari, 2022, American journal of hematology.

Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings

D. Neuberg, Catherine J. Wu, S. Rodig, 2020 .

Improving the efficiency of PBPC collection by pre-apheresis peripheral blood and mid-apheresis product measurements of CD34 cells.

T. Lane, E. Ball, A. Bashey, 2004, Cytotherapy.

Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration

Shannon R. McCurdy, R. Varadhan, L. Gondek, 2023, Research square.

Ipilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant naïve settings.

D. Neuberg, Catherine J. Wu, J. Ritz, 2022, Blood.

Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration.

Shannon R. McCurdy, R. Varadhan, L. Gondek, 2023, Haematologica.

Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product

Stephen M. Shaw, P. Westervelt, J. Dipersio, 2018, Blood.

Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002).

K. Owzar, S. Farag, T. Shea, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission.

J. Armitage, J. Vose, M. Horowitz, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry.

J. Armitage, J. Vose, E. Montserrat, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)

Catherine J. Wu, S. Nikiforow, P. Armand, 2018, Blood.

A unique schedule of palonosetron, ondansetron, and dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy

A. Bashey, K. Holland, S. Solomon, 2017, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

M. Solh, S. Solomon, A. Bashey, 2019, Blood.

A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

I. Yakoub-Agha, M. Aljurf, R. Gale, 2023, Blood advances.

Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant

M. Solh, S. Solomon, A. Bashey, 2023, Blood advances.

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

F. Hodi, P. Armand, M. Davids, 2016, The New England journal of medicine.

Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

B. Sandmaier, M. Aljurf, R. Gale, 2019, Blood advances.

Fevers post infusion of T-cell replete hla mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes

E. Dickhaus, M. Solh, S. Solomon, 2019, Bone Marrow Transplantation.

The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation

S. Solomon, D. Blaise, A. Nagler, 2019, Bone Marrow Transplantation.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia.

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical Transplantation with Post-transplant Cyclophosphamide for High-risk Acute Lymphoblastic Leukemia

S. Solomon, A. Bashey, D. Milton, 2017 .

Running Title: Haploidentical vs. Unrelated Donor Transplant

M. Horowitz, P. Armand, S. Devine, 2015 .

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

R. Vij, M. Perales, F. Appelbaum, 2015, Blood.

The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia.

M. Norkin, B. Sandmaier, B. George, 2019, Blood advances.

Survival after T-Cell Replete Haplo-Identical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor Transplant for Acute Myeloid Leukemia

R. Vij, M. Perales, F. Appelbaum, 2014 .

Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome

S. Solomon, A. Bashey, L. Morris, 2012 .